Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
Related Questions
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
How do you approach the management of aortitis in patients with ANCA-associated vasculitis?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
